Special Senses & Otolaryngology

Allergic rhinitis: stepwise management

Clinical Overview and When to Suspect Allergic Rhinitis

— Affects ~10–30% of US adults and up to 40% of children; one of the most common chronic conditions seen in primary care.

— Major contributor to lost school/work productivity, sleep disturbance, and reduced quality of life — often underestimated by clinicians.

— Frequently coexists with asthma, atopic dermatitis, and eosinophilic esophagitis ("atopic march").

— Intermittent: symptoms <4 days/week OR <4 consecutive weeks.

— Persistent: symptoms ≥4 days/week AND ≥4 consecutive weeks.

— Severity graded mild vs moderate–severe based on sleep impairment, impact on daily activity/school/work, and troublesome symptoms.

— Recurrent "colds" lasting >10–14 days without fever.

— Bilateral clear rhinorrhea, itching, and seasonal/exposure pattern (cats, pollen, dust mites, cockroach, mold).

— Allergic shiners, transverse nasal crease ("allergic salute"), mouth breathing in a child.

— Family history of atopy; comorbid asthma worsening during pollen season.

— Uncontrolled AR worsens asthma control and increases sinusitis and otitis media risk.

— Stepwise outpatient management is highly testable: avoidance → intranasal corticosteroid → add-ons → immunotherapy referral.

Board pearl: If a patient reports "chronic sinus infections" treated repeatedly with antibiotics but has bilateral clear discharge, itching, and a pale/boggy turbinate exam — suspect underlying allergic rhinitis driving recurrent sinus symptoms, and treat the AR rather than re-prescribing antibiotics. This is a classic Step 3 ambulatory stewardship stem.

Definition: IgE-mediated inflammation of nasal mucosa triggered by inhaled allergens, producing the classic tetrad of sneezing, rhinorrhea, nasal congestion, and nasal/ocular pruritus.

Epidemiology and burden:

Classification (ARIA framework, preferred over old seasonal/perennial split):

When to suspect on Step 3 vignettes:

Why it matters for the family physician:

Presentation Patterns and Key History

— Sneezing in paroxysms, often in the morning or on allergen exposure.

— Rhinorrhea — bilateral, clear, watery (purulent/unilateral suggests alternative dx).

— Nasal congestion/obstruction — often the most bothersome adult complaint, may cause snoring and disturbed sleep.

— Pruritus of nose, palate, eyes, throat, ears — itch is the symptom that most reliably distinguishes AR from non-allergic rhinitis.

— Seasonal: spring (tree), summer (grass), late summer/fall (ragweed/weed), variable (mold spores).

— Perennial: dust mites, cockroach, pet dander, indoor mold — symptoms year-round, worse at night/morning in bedroom.

— Occupational: flour, latex, animal proteins, wood dust — symptoms improve on weekends/vacation.

— New pet, moving to a humid home, basement bedroom, stuffed animals, carpeting.

— Smoke, strong odors, perfumes, cold air → suggest non-allergic (vasomotor) overlap.

— Asthma (wheeze, exercise cough, nocturnal cough) — present in up to 40% of AR patients.

— Atopic dermatitis, food allergy, eosinophilic esophagitis.

— Obstructive sleep apnea, chronic rhinosinusitis, otitis media with effusion in children.

— Conjunctival symptoms ("allergic rhinoconjunctivitis").

— Sleep quality, daytime fatigue, school/work absenteeism, sports performance, mood.

— Validated tools: RQLQ or simple symptom diary; not required on boards but recognized.

— Chronic decongestant nasal spray use >5 days → rhinitis medicamentosa.

— ACEi, beta-blockers, hormonal contraceptives, cocaine — drug-induced rhinitis mimics.

Key distinction: Itching + clear bilateral rhinorrhea + seasonality = allergic. No itch + congestion triggered by temperature/odors = vasomotor (non-allergic). This single question is often the discriminator on vignette stems.

Cardinal symptoms (must elicit all four):

Temporal pattern — extract this on history:

Triggers and modifiers to ask about:

Comorbidity screen (high-yield for Step 3):

Impact assessment (drives severity classification and therapy intensity):

Medication/exposure history:

Physical Exam Findings and Severity Assessment

— Allergic shiners: infraorbital darkening from venous stasis.

— Dennie–Morgan lines: infraorbital skin folds, indicate chronic atopy.

— Allergic salute and transverse nasal crease across the lower third of the nose (children).

— Mouth breathing, open-mouth posture, "adenoid facies" in chronic pediatric cases.

— Pale, bluish-gray, boggy, edematous turbinates with clear watery secretions = classic AR.

— Erythematous turbinates with purulent discharge → think infection/sinusitis instead.

— Look for nasal polyps (gray, glistening, insensate masses) — if present in a child, screen for cystic fibrosis; in adults, think aspirin-exacerbated respiratory disease (AERD).

— Septal deviation or perforation (cocaine, chronic decongestant abuse).

— Cobblestoning of posterior pharyngeal wall (lymphoid hyperplasia from postnasal drip).

— High-arched palate in chronic mouth breathers.

— Tonsillar/adenoidal hypertrophy in children.

— Conjunctival injection, chemosis, tearing, "Dennie" folds, sometimes cobblestone tarsal conjunctiva (vernal/perennial allergic conjunctivitis).

— Retracted TM, air–fluid level, or serous effusion (eustachian tube dysfunction from nasal congestion).

— Always auscultate — wheezing or prolonged expiration mandates evaluation for concomitant asthma.

Step 3 management: When you see pale boggy turbinates + cobblestoning + allergic shiners, you have enough to start empiric therapy with an intranasal corticosteroid (INCS) without further testing in a typical outpatient visit — clinical diagnosis is the rule.

General appearance clues:

Anterior rhinoscopy (key exam):

Oropharynx:

Eyes:

Ears:

Chest:

Skin: atopic dermatitis flexural changes support the atopic diathesis.

Hemodynamics: not applicable in routine AR, but in anaphylaxis (a same-spectrum IgE disorder), look for hypotension, stridor, urticaria — those patients need epinephrine, not antihistamines.

Diagnostic Workup — When and What to Test Initially

— Symptoms inadequately controlled despite optimal pharmacotherapy.

— Need to identify specific triggers for targeted avoidance or immunotherapy candidacy.

— Occupational rhinitis with disability implications.

— Atypical features (unilateral symptoms, epistaxis, anosmia, facial pain) requiring exclusion of structural disease first.

— Skin prick testing (SPT): preferred — rapid (15 min), sensitive, inexpensive, results visible to patient (motivates adherence).

· Hold H1 antihistamines for 5–7 days prior (cause false negatives).

· Avoid in severe eczema, dermatographism, recent anaphylaxis, uncontrolled asthma, or while on beta-blockers (impair epinephrine rescue if reaction occurs).

— Allergen-specific serum IgE (ImmunoCAP, formerly RAST):

· Use when SPT contraindicated, on antihistamines that cannot be stopped, or extensive skin disease.

· More expensive, no need to stop antihistamines, slightly lower sensitivity.

— Total serum IgE alone (nonspecific, often normal in AR).

— Peripheral eosinophil count (low sensitivity).

— Food allergy panels for nasal symptoms.

— IgG food panels (no evidence base).

— Not indicated for uncomplicated AR.

— CT sinus without contrast only if chronic rhinosinusitis, polyps, anatomic obstruction, or treatment failure is suspected.

Board pearl: A patient on a daily antihistamine reports negative skin testing — this is a false negative due to H1 blockade. Either repeat SPT after a 5–7 day washout or order serum-specific IgE instead.

Allergic rhinitis is fundamentally a clinical diagnosis. Routine testing is not required if history and exam are classic and the patient responds to empiric therapy. Step 3 frequently penalizes over-testing.

Indications to pursue formal allergen testing:

First-line confirmatory testing options:

Tests that are NOT helpful (avoid on boards):

Imaging:

Nasal cytology (rarely tested): eosinophils suggest AR or NARES; neutrophils suggest infection.

Diagnostic Workup — Advanced and Confirmatory Studies

— Indicated for unilateral symptoms, epistaxis, anosmia, suspected polyps, structural abnormality, or persistent symptoms despite optimized therapy.

— Directly visualizes middle meatus, polyps, septal deviation, masses, adenoid hypertrophy.

— Gold standard for assessing chronic rhinosinusitis, nasal polyposis, anatomic blockage.

— Order after failure of medical therapy or before surgical referral, not as a screening tool.

— Look for mucosal thickening, ostiomeatal complex obstruction, polyps, opacified sinuses.

— Obtain spirometry with bronchodilator response in any AR patient with cough, wheeze, dyspnea, or exercise intolerance — unmasking asthma is a high-yield Step 3 maneuver because asthma comorbidity changes the long-term plan.

— Component-resolved diagnostics (e.g., Bet v 1, Fel d 1) — refines cross-reactivity and immunotherapy choices.

— Nasal provocation testing — research/occupational settings.

— Suspected CSF rhinorrhea (clear unilateral drip after head trauma or surgery): test fluid for beta-2 transferrin (specific) or beta-trace protein.

— Suspected granulomatosis with polyangiitis (crusting, septal perforation, saddle nose): ANCA, urinalysis, CXR/CT, biopsy.

— Suspected CF (pediatric polyps, recurrent sinopulmonary infections): sweat chloride.

— Suspected AERD: history of asthma + polyps + NSAID reaction; consider aspirin challenge with allergist.

Key distinction: Unilateral nasal symptoms = red flag. Bilateral pruritic rhinorrhea is AR; unilateral discharge, obstruction, bleeding, or anosmia mandates endoscopy and imaging to exclude polyp, foreign body (especially toddlers), tumor (inverted papilloma, nasopharyngeal carcinoma), or CSF leak.

When initial workup is equivocal or refractory, escalate evaluation:

Nasal endoscopy (ENT referral):

CT sinuses without contrast:

Pulmonary function testing:

Specialized allergy workup (allergist referral):

Workup for differential conditions:

Tympanometry/audiometry: in children with persistent effusions and conductive hearing loss.

Stepwise Management Logic — The Ambulatory Algorithm

— Dust mites: allergen-impermeable mattress/pillow encasings, wash bedding weekly in hot water (≥130°F), reduce indoor humidity <50%, remove bedroom carpeting and stuffed animals.

— Pet dander: ideal is removal; if unwilling, keep pet out of bedroom, HEPA filtration, weekly pet bathing (modest benefit).

— Pollen: keep windows closed during peak season, shower/change clothes after outdoor exposure, run AC, check daily pollen counts.

— Cockroach/mold: integrated pest management, fix water leaks, dehumidify basements.

— Tobacco smoke: counsel cessation/avoidance — non-specific irritant that worsens all rhinitis.

— Oral second-generation H1 antihistamine (cetirizine, loratadine, fexofenadine, levocetirizine) PRN or daily, OR

— Intranasal antihistamine (azelastine, olopatadine) PRN.

— Intranasal corticosteroid (INCS) daily (fluticasone, mometasone, triamcinolone, budesonide) — single most effective monotherapy for AR, addressing all four symptom domains including congestion.

— Add intranasal antihistamine (combination fluticasone/azelastine spray) — superior to either alone.

— Or add oral antihistamine if ocular/systemic symptoms dominate.

— Add intranasal ipratropium for refractory rhinorrhea.

— Short course (≤5 days) oral decongestant for acute congestion bursts only.

— Refer for allergen immunotherapy (SCIT or SLIT) — disease-modifying.

— Consider omalizumab in severe coexisting allergic asthma.

Step 3 management: The single best initial pharmacologic agent for moderate–severe persistent allergic rhinitis is a daily intranasal corticosteroid, not an oral antihistamine — this is the most repeatedly tested decision point.

Step 0 — Environmental control and trigger avoidance (always first, always continued):

Step 1 — Mild/intermittent symptoms:

Step 2 — Moderate–severe or persistent symptoms (most testable answer):

Step 3 — Inadequate control on INCS alone:

Step 4 — Still uncontrolled despite combination therapy:

Pharmacotherapy — First-Line Drug Regimens in Depth

— Examples: fluticasone propionate, fluticasone furoate, mometasone, triamcinolone, budesonide, ciclesonide, beclomethasone.

— Onset: noticeable benefit in 12 hours, maximum effect at 2 weeks — counsel patients to use daily, not PRN, and persist before judging efficacy.

— Technique counseling (high-yield): aim spray laterally toward the ipsilateral ear, NOT toward the septum, do not sniff hard — reduces epistaxis and septal perforation.

— Adverse effects: nasal dryness, epistaxis (most common), rarely septal perforation, minimal systemic absorption (fluticasone furoate and mometasone have lowest bioavailability — preferred when systemic steroid effects are a concern).

— Safe in pregnancy (budesonide best-studied) and in children ≥2 years (mometasone, fluticasone furoate).

— Cetirizine, loratadine, fexofenadine, levocetirizine, desloratadine — non-sedating (cetirizine mildly sedating), preferred for sneezing/itch/rhinorrhea.

— Less effective than INCS for congestion.

— Anticholinergic burden, sedation, impaired driving and learning, AGS Beers list in elderly (delirium, falls, urinary retention).

— Azelastine, olopatadine — onset within 15 min, work PRN, useful add-on.

— Side effects: bitter taste, mild somnolence.

— Montelukast — modest efficacy, FDA black-box warning for neuropsychiatric effects (depression, suicidality). Reserve for AR + asthma when other agents inadequate.

— Oral pseudoephedrine — caution in HTN, CAD, BPH, hyperthyroidism, insomnia.

— Topical oxymetazoline — limit to ≤3–5 days to avoid rhinitis medicamentosa.

Board pearl: A patient on daily oxymetazoline for 2 months presents with worsening congestion — diagnosis is rhinitis medicamentosa; treat by stopping the decongestant and starting an INCS (± short oral steroid taper in severe cases).

Intranasal corticosteroids (INCS) — the workhorse:

Second-generation oral antihistamines:

Avoid first-generation antihistamines (diphenhydramine, chlorpheniramine, hydroxyzine):

Intranasal antihistamines:

Leukotriene receptor antagonist:

Intranasal cromolyn: safe but requires QID dosing; useful pre-exposure prophylaxis (e.g., before yardwork).

Intranasal ipratropium: targets rhinorrhea only, especially gustatory and cold-air-induced.

Decongestants:

Allergen Immunotherapy and Refractory Disease Management

— Indications:

· Inadequate symptom control despite environmental control + optimized pharmacotherapy.

· Patient preference to reduce long-term medication burden.

· Coexisting allergic asthma or atopic comorbidity.

· Demonstrated specific IgE sensitization (positive SPT or serum specific IgE) correlating with clinical symptoms — sensitization without symptoms is not an indication.

— Multi-allergen mixtures possible; build-up phase weekly for ~3–6 months, then maintenance every 2–4 weeks for 3–5 years.

— Must be administered in a clinic equipped to manage anaphylaxis; patient observed 30 minutes post-injection.

— Risk: local reactions common; systemic anaphylaxis ~1/1000 injections — beta-blockers and ACE inhibitors are relative contraindications (impair epinephrine response, potentiate reactions).

— FDA-approved for grass, ragweed, dust mite in the US.

— Self-administered daily at home; first dose must be given in clinic with observation.

— Prescribe an epinephrine autoinjector for home use.

— Contraindications: severe/unstable asthma, eosinophilic esophagitis (for SLIT).

— Omalizumab (anti-IgE) — approved for severe allergic asthma and chronic urticaria; off-label in refractory AR.

— Dupilumab — used when AR coexists with severe asthma, atopic dermatitis, or chronic rhinosinusitis with nasal polyps.

— Inferior turbinate reduction for refractory mechanical congestion from turbinate hypertrophy unresponsive to INCS.

— Septoplasty if obstructive deviation contributes.

— Functional endoscopic sinus surgery (FESS) if chronic rhinosinusitis with polyps coexists.

— Reserve for severe acute flares unresponsive to maximal topical therapy; never use depot intramuscular steroids for AR (cumulative HPA suppression, no evidence advantage).

CCS pearl: Order environmental modifications, INCS daily, and allergist referral simultaneously when a patient has failed two months of combination INCS + antihistamine — do not keep adding oral steroids.

Allergen immunotherapy (AIT) — the only disease-modifying treatment:

Subcutaneous immunotherapy (SCIT):

Sublingual immunotherapy (SLIT) tablets:

Biologics (specialist domain):

Surgical adjuncts:

Brief oral corticosteroid bursts:

Special Populations — Elderly and Renal/Hepatic Impairment

— Distinguish AR from age-related rhinitis (atrophic, watery rhinorrhea without itch or seasonality, often nasal valve collapse contributing).

— Drug-induced rhinitis is more common: ACE inhibitors, alpha-blockers (doxazosin, tamsulosin), PDE5 inhibitors, beta-blockers, hormonal therapy — review medication list before adding new therapy.

— Avoid first-generation antihistamines (diphenhydramine, chlorpheniramine, hydroxyzine) — Beers list: anticholinergic delirium, urinary retention, falls, cognitive impairment.

— Avoid systemic decongestants (pseudoephedrine, phenylephrine) in patients with HTN, CAD, arrhythmia, BPH, glaucoma, hyperthyroidism — all common in elderly.

— INCS remain first line; prefer fluticasone furoate or mometasone (lowest systemic bioavailability, less concern for osteoporosis, cataracts, glaucoma with chronic use).

— Monitor for epistaxis — elderly often on anticoagulants/antiplatelets; counsel proper spray technique and humidification.

— Cetirizine and levocetirizine: renally cleared — reduce dose in CrCl <50 mL/min (e.g., cetirizine 5 mg daily).

— Fexofenadine: also renally adjusted; reduce dose with CrCl <80 mL/min.

— Loratadine and desloratadine: primarily hepatic; minor renal adjustment.

— Intranasal medications are minimally absorbed — generally safe across CKD.

— Loratadine, desloratadine, fexofenadine — caution with severe hepatic disease; consider dose reduction.

— Montelukast — rare hepatotoxicity, monitor LFTs if baseline disease.

— Topical agents preferred.

— Check for QT-prolonging combinations (older antihistamines, certain antifungals).

— Reassess medication necessity annually — deprescribing is a Step 3 competency.

Step 3 management: For an 80-year-old with new-onset clear rhinorrhea after starting lisinopril, the correct first step is discontinue the ACE inhibitor (switch to an ARB if needed) — not to layer on antihistamines.

Older adults (≥65):

Renal impairment:

Hepatic impairment:

Polypharmacy considerations:

Special Populations — Pregnancy, Pediatrics, and Athletes

— Pregnancy itself can cause rhinitis of pregnancy (congestion ≥6 weeks in last trimester, resolves within 2 weeks postpartum, no allergic etiology) — manage with saline irrigation, nasal strips, head-of-bed elevation; reassure.

— For true AR in pregnancy, prefer non-pharmacologic measures first: saline irrigation, allergen avoidance, HEPA filtration.

— Safe pharmacotherapy:

· Intranasal corticosteroids: budesonide is best-studied (formerly category B).

· Second-generation antihistamines: loratadine and cetirizine preferred; chlorpheniramine has the longest safety record but is sedating.

· Cromolyn intranasal: very safe.

— Avoid: oral decongestants in first trimester (pseudoephedrine — gastroschisis concern); montelukast unless required for asthma; immunotherapy initiation (do not start during pregnancy, but maintenance can be continued at the same dose).

— AR is rare before age 2; suspect alternatives (foreign body if unilateral foul-smelling discharge, adenoid hypertrophy, viral).

— Mometasone and fluticasone furoate approved from age 2; second-generation oral antihistamines approved as young as 6 months (cetirizine).

— Avoid first-generation antihistamines in young children — paradoxical excitation, anticholinergic toxicity, deaths reported in infants.

— Address school performance and sleep impact; uncontrolled AR worsens asthma, otitis media with effusion, and learning.

— SLIT tablets approved down to age 5 (some) or 18 (others); SCIT generally ≥5 years.

— Monitor growth velocity with chronic INCS (effect is small and typically transient).

— Many oral decongestants (pseudoephedrine) are banned/restricted by WADA above threshold concentrations — counsel before prescribing for competitive athletes.

— INCS and second-generation antihistamines are permitted.

Board pearl: For a pregnant patient with troublesome AR, the safest evidence-based regimen is saline irrigation + intranasal budesonide ± loratadine; do not initiate allergen immunotherapy during pregnancy.

Pregnancy:

Pediatrics:

Athletes:

Complications and Adverse Outcomes

— Acute and chronic rhinosinusitis: persistent mucosal inflammation impairs ostiomeatal drainage → bacterial superinfection. Suspect when symptoms persist >10 days, double-worsen, or include unilateral facial pain and purulent discharge.

— Chronic rhinosinusitis with nasal polyposis (CRSwNP): polyps, anosmia, refractory congestion.

— Otitis media with effusion (OME): especially in children — eustachian tube dysfunction from nasal congestion → conductive hearing loss → speech delay.

— Adenoid hypertrophy in pediatrics, contributing to mouth breathing, snoring, and obstructive sleep apnea.

— Uncontrolled AR worsens asthma control; treating AR with INCS reduces asthma exacerbations and ED visits.

— AR is a risk factor for new-onset asthma in children.

— Disrupted sleep architecture, daytime fatigue, irritability.

— Reduced school/work performance, increased motor vehicle risk (worsened if treated with first-gen antihistamines).

— Anxiety and depression risk modestly elevated.

— Social withdrawal during peak season.

— Epistaxis from INCS — most common; technique correction usually solves it.

— Septal perforation from chronic INCS aimed at septum or from cocaine/oxymetazoline abuse.

— Rhinitis medicamentosa from prolonged topical decongestant use.

— HPA-axis suppression is rare with modern INCS at standard doses, but cumulative with concomitant inhaled steroids for asthma — consider when patients use multiple steroid routes.

— Systemic anaphylaxis from SCIT — rare but potentially fatal; mandates clinic observation.

— High-arched palate, dental malocclusion, "long face syndrome."

Key distinction: Persistent unilateral congestion plus purulent discharge, fever, and facial pain >10 days suggests bacterial sinusitis — not simply an AR flare — and warrants targeted antibiotics (amoxicillin-clavulanate) per IDSA/AAO-HNS.

Direct mucosal and adjacent-structure complications:

Asthma interaction (the "united airways" concept):

Sleep and neurocognitive consequences:

Psychosocial and quality-of-life:

Treatment-related complications:

Dental and craniofacial (chronic pediatric mouth breathing):

When to Escalate Care — Referral and Inpatient Triage

— Symptoms persist despite 3 months of guideline-based therapy including INCS + intranasal or oral antihistamine.

— Allergen-specific testing is needed to guide avoidance or immunotherapy.

— Patient is a candidate for SCIT or SLIT.

— Concomitant difficult-to-control asthma, atopic dermatitis, eosinophilic esophagitis, or chronic urticaria.

— Suspected food allergy, insect venom allergy, drug allergy, or AERD.

— Unilateral symptoms, recurrent epistaxis, anosmia, or facial pain.

— Nasal polyps on exam.

— Suspected structural cause: septal deviation, turbinate hypertrophy, choanal atresia (pediatric).

— Chronic rhinosinusitis refractory to medical therapy (consider FESS).

— Suspected mass, CSF leak, granulomatous disease.

— Anaphylaxis during immunotherapy or with food/venom exposure — intramuscular epinephrine 0.3–0.5 mg (adult) in lateral thigh, repeat q5–15 min, IV fluids, observe 4–6 hours minimum; biphasic reaction risk up to 20%.

— Severe acute angioedema compromising airway → ED, secure airway.

— Periorbital/orbital cellulitis from acute sinusitis: IV antibiotics, ENT and ophthalmology consult, CT orbits; intraorbital abscess requires surgical drainage.

— Intracranial extension of sinusitis (cavernous sinus thrombosis, meningitis, brain abscess) — emergent neurosurgery and ID.

— Hemodynamic instability, altered mental status, visual changes, severe headache, periorbital edema with restricted EOM, or systemic toxicity.

CCS pearl: A patient mid-SCIT build-up with hypotension, urticaria, wheezing post-injection — stop the infusion of allergen, give IM epinephrine immediately, place supine with legs elevated, start O2 and IV fluids, observe 4–6 hours before discharge with epinephrine autoinjector prescription.

Allergic rhinitis is essentially an ambulatory disease, but escalation is warranted in specific scenarios.

Refer to allergy/immunology when:

Refer to ENT/otolaryngology when:

Urgent/emergent escalation (rare in AR alone, but tested):

Inpatient admission triggers (sinusitis complications, not AR per se):

Key Differentials — Other Forms of Rhinitis

— Adult-onset, perennial congestion and clear rhinorrhea without itching or sneezing paroxysms, triggered by temperature changes, strong odors, alcohol, spicy food ("gustatory rhinitis"), or emotion.

— Negative allergen testing.

— Treatment: intranasal antihistamine (azelastine) and/or intranasal ipratropium are most effective; INCS less effective than for AR but often used.

— Acute, self-limited (7–10 days), associated with fever, myalgia, sore throat; discharge starts clear then becomes purulent; resolves spontaneously.

— Perennial, eosinophils on nasal smear, negative allergy testing; may evolve into AERD.

— Responds well to INCS.

— From topical decongestant overuse (>5 days); rebound congestion; treat by stopping the spray + INCS.

— ACE inhibitors, alpha-blockers (tamsulosin, doxazosin), beta-blockers, PDE5 inhibitors (sildenafil), hormonal therapy/OCPs, NSAIDs (AERD), aspirin, cocaine, gabapentin.

— Pregnancy, hypothyroidism, OCPs; resolves with treating underlying cause.

— Elderly or post-surgical; foul smell ("ozena"), crusting, wide nasal cavity.

— Improves on weekends/vacation; consider workplace allergen or irritant.

Key distinction: Itch + sneezing paroxysms + clear rhinorrhea + IgE sensitization = allergic. No itch, triggered by temperature/odors, negative IgE testing = non-allergic (vasomotor) — and these patients respond better to azelastine ± ipratropium than to oral antihistamines, which is the testable management nuance.

Non-allergic (vasomotor/idiopathic) rhinitis:

Mixed rhinitis: features of both allergic and non-allergic — extremely common in adults; manage both.

Infectious rhinitis (viral URI):

NARES (Non-Allergic Rhinitis with Eosinophilia Syndrome):

Rhinitis medicamentosa:

Drug-induced rhinitis:

Hormonal rhinitis:

Atrophic rhinitis:

Occupational rhinitis:

Key Differentials — Non-Rhinitis Causes of Nasal Symptoms

— Deviated nasal septum — unilateral obstruction not responsive to medications.

— Nasal polyposis — bilateral obstruction, anosmia, often with asthma (Samter triad if NSAID-sensitive).

— Adenoid hypertrophy (pediatric) — mouth breathing, snoring, OME.

— Choanal atresia — neonatal cyanosis relieved by crying, unilateral persistent rhinorrhea in older children.

— Foreign body — toddler with unilateral foul-smelling purulent discharge ± epistaxis.

— Inverted papilloma — unilateral, locally aggressive, malignant potential.

— Nasopharyngeal carcinoma — adult with unilateral epistaxis, otalgia, conductive hearing loss, cervical lymphadenopathy; EBV-associated, more common in East Asian populations.

— Juvenile nasopharyngeal angiofibroma — adolescent male with recurrent epistaxis and obstruction.

— Esthesioneuroblastoma — anosmia + unilateral mass.

— Granulomatosis with polyangiitis (GPA): crusting, septal perforation, saddle-nose deformity, hemoptysis, hematuria, c-ANCA/PR3 positive.

— Sarcoidosis: uveitis, lymphadenopathy, skin lesions, nasal mucosal nodularity.

— Eosinophilic granulomatosis with polyangiitis (EGPA): asthma + eosinophilia + neuropathy.

— Clear unilateral drip after head trauma, sinus surgery, or spontaneous (idiopathic intracranial hypertension); halo sign, positive beta-2 transferrin, salty taste, risk of meningitis.

— Hypothyroidism, primary ciliary dyskinesia (situs inversus + bronchiectasis + chronic sinusitis), cystic fibrosis (pediatric polyps).

— Cluster headache and migraine may produce unilateral rhinorrhea/congestion — pain dominates the syndrome.

Board pearl: Saddle-nose deformity + septal perforation + hematuria → GPA until proven otherwise; order c-ANCA/PR3, urinalysis, creatinine, CT chest and refer to rheumatology — this is not allergic rhinitis.

Structural/mechanical:

Neoplastic:

Granulomatous and inflammatory:

CSF rhinorrhea:

Systemic/metabolic mimics:

Migraine and trigeminal autonomic cephalalgias:

Secondary Prevention and Long-Term Plan

— Sustained allergen avoidance is the bedrock — review and reinforce at every visit; written action plans improve adherence.

— Daily intranasal corticosteroid during symptomatic seasons or year-round for perennial disease; emphasize that effect builds over 2 weeks and adherence is essential.

— Step-down therapy during low-symptom periods (off-season) to lowest effective regimen — minimize medication burden and side effects.

— Annual reassessment of severity, control, and triggers; revisit immunotherapy candidacy if persistent.

— If asthma comorbid, ensure inhaled corticosteroid–based regimen per GINA, asthma action plan, and adherence/inhaler technique check; treating AR improves asthma control.

— Annual influenza, age-appropriate COVID-19, pneumococcal as indicated — reduce viral triggers that compound AR.

— Standard USPSTF screening should not be deferred for AR.

— Counsel tobacco/vape cessation; address secondhand smoke and wood-burning stoves; check local AQI during wildfire seasons.

— Symptom diary, pollen-count awareness apps, peak-flow if asthma comorbid.

— Identify "red flag" symptoms (unilateral bleeding, persistent facial pain, anosmia, vision change) that warrant urgent return.

— Continue SCIT/SLIT for full 3–5 year course to achieve durable disease modification — early discontinuation often results in relapse.

— Treat OSA (often unmasked once AR controlled and nasal airflow improves — recheck after 3 months).

— Optimize atopic dermatitis and eosinophilic conditions in collaboration with dermatology/GI.

Step 3 management: At a routine follow-up for well-controlled AR on daily INCS, the correct long-term plan is to continue INCS through the symptomatic season, reinforce avoidance, and consider stepping down to PRN during off-season — not to indefinitely escalate therapy.

Foundational pillars of long-term control:

Asthma co-management (united airways approach):

Vaccinations and preventive care:

Smoking cessation and air quality:

Patient self-monitoring:

Immunotherapy maintenance and de-escalation:

Comorbid condition optimization:

Follow-Up, Monitoring, and Counseling Cadence

— Reassess at 2–4 weeks after initiating INCS to confirm response and reinforce technique — most failures are due to incorrect spray angle, poor adherence, or premature judgment of effect.

— If suboptimal, verify adherence first, then step up per algorithm.

— Stable, well-controlled AR: routine follow-up every 6–12 months as part of preventive care; combine with chronic disease visits.

— Moderate–severe or asthma comorbidity: every 3–6 months until stable.

— Patients on immunotherapy: per allergist; primary care monitors for adherence, side effects, and reaction history.

— Symptom frequency, severity, and impact on sleep/work/school.

— Days of rescue medication use.

— Asthma control (ACT score if comorbid).

— Medication side effects: epistaxis, taste disturbance, sedation, mood (montelukast).

— Spray technique re-demonstration annually.

— Growth velocity in pediatric patients on chronic INCS.

— Ocular pressure and lens checks in patients on high-dose chronic INCS with risk factors (rarely required at standard doses).

— Spray technique: lean head slightly forward, opposite hand to opposite nostril, aim lateral, no hard sniff, breathe gently.

— Adherence: AR is chronic — daily INCS during active periods.

— Driving safety if any sedating agent prescribed.

— Environmental modifications: discuss financial accessibility (mattress encasings ~$30–60 — often more affordable than monthly meds).

— When to call: worsening despite optimized therapy, unilateral symptoms, bleeding, vision change, severe headache, suspected anaphylaxis.

— Communicate the AR action plan to school nurses/employers; document allergen list for emergency settings.

CCS pearl: When prescribing an INCS, order a 2-week follow-up phone or telehealth check and explicitly demonstrate spray technique — this single counseling intervention prevents most "treatment failures."

Initial follow-up after starting therapy:

Ongoing monitoring intervals:

Parameters to track at each visit:

Counseling priorities:

Care transitions:

Ethical, Legal, and Patient Safety Considerations

— SCIT and SLIT carry small but real risk of anaphylaxis and death. Document discussion of risks, benefits, alternatives, time commitment (3–5 years), and need for in-clinic observation.

— For SLIT, document first-dose-in-clinic protocol and epinephrine autoinjector prescription with training (technique, expiration date, when to use, calling 911 after use).

— Pediatric assent in addition to parental consent for older children/adolescents.

— Montelukast carries an FDA boxed warning for neuropsychiatric events including depression and suicidality — counsel and document; reassess at follow-up. Use only when alternatives are inadequate.

— Avoid first-generation antihistamines in elderly (Beers criteria) and young children — document rationale if used.

— When transitioning a patient between PCP, allergist, and ENT, ensure the medication list, allergen sensitization profile, and asthma action plan transfer — fragmented care leads to duplicate prescribing and gaps.

— Reconcile medications at every visit; identify drug-induced rhinitis (ACEi, tamsulosin) before adding new agents — a classic Step 3 safety scenario.

— Occupational rhinitis may trigger workers' compensation evaluation; document exposure history and consider workplace accommodation letters.

— Pseudoephedrine restrictions: Combat Methamphetamine Epidemic Act (CMEA) limits pharmacy purchases; competitive athletes face WADA restrictions.

— Counsel and document the driving risk of first-generation antihistamines; some states have impaired-driving statutes that apply to OTC sedating meds.

— INCS over-the-counter access (fluticasone, triamcinolone, budesonide) improves equity; choose OTC options when cost is a barrier rather than prescribing a more expensive Rx-only equivalent.

— Suspected child neglect when severe environmental triggers (mold, infestations) persist in a child's home → involve social work; consider mandated reporting if hazardous neglect.

Board pearl: Before prescribing montelukast for AR, document a discussion of neuropsychiatric risk and confirm that INCS ± intranasal antihistamine were tried first — failure to do so is the testable safety lapse.

Informed consent for immunotherapy:

Black-box and prescribing safety:

Patient safety and transitions of care:

Occupational and disability considerations:

Sedation and driving:

Equity and access:

Mandatory considerations:

High-Yield Associations and Rapid-Fire Facts

Key distinction: Step 2 favors recognition of the syndrome; Step 3 favors the stepwise outpatient algorithm, drug-specific safety, and longitudinal follow-up cadence — focus your final review on the management logic in chunks 6–8 and 15–17.

Atopic march: atopic dermatitis (infancy) → food allergy → allergic rhinitis → asthma. Step 3 vignettes use the sequence to set up comorbidities.

Samter triad / AERD: asthma + nasal polyps + NSAID/aspirin sensitivity; treat with INCS, leukotriene modifiers, consider aspirin desensitization.

Allergic salute → transverse nasal crease in chronic pediatric AR.

Dennie–Morgan lines and allergic shiners — atopic stigmata on inspection.

Pale, boggy, blue-gray turbinates — anterior rhinoscopy hallmark of AR.

Cobblestoning of posterior pharynx — chronic postnasal drip.

Eosinophils on nasal smear — AR or NARES; neutrophils — infection.

Beta-2 transferrin in nasal fluid → diagnostic of CSF rhinorrhea.

Halo sign on tissue (clear ring around bloody center) — CSF leak.

Saddle nose + septal perforation — GPA, cocaine, syphilis, leprosy.

Unilateral foul-smelling discharge in a toddler — nasal foreign body.

Unilateral epistaxis + obstruction in adolescent male — juvenile nasopharyngeal angiofibroma.

EBV-associated nasopharyngeal carcinoma — adult with unilateral nasal symptoms + cervical node + serous otitis media.

Most effective monotherapy for AR — intranasal corticosteroid.

Onset of INCS effect — 12 hours, max at 2 weeks.

Best INCS in pregnancy — budesonide.

Best second-generation antihistamines in pregnancy — loratadine, cetirizine.

Rhinitis medicamentosa — topical decongestant >5 days; treat by stopping spray + INCS.

Montelukast — FDA boxed warning for neuropsychiatric effects.

Immunotherapy duration — 3–5 years for disease modification.

Hold antihistamines 5–7 days before skin prick testing.

Beta-blockers + immunotherapy — increased anaphylaxis severity, harder to rescue.

WADA-banned — oral pseudoephedrine above threshold in competition.

OME in children — most common cause of conductive hearing loss; AR is a major contributor.

AR worsens asthma; treating AR improves asthma control.

Board Question Stem Patterns

— A 24-year-old with springtime sneezing, clear rhinorrhea, itchy eyes, pale boggy turbinates. Best initial therapy? → Daily intranasal corticosteroid (not oral antihistamine alone).

— A 28-year-old at 22 weeks with worsening AR. Best therapy? → Saline irrigation + intranasal budesonide, ± loratadine. Avoid oral decongestants.

— Worsening congestion after weeks of OTC oxymetazoline. Next step? → Stop the decongestant + start INCS; not increase the decongestant.

— Elderly man with new clear rhinorrhea after starting lisinopril/tamsulosin. Next step? → Discontinue/switch the offending drug, not add antihistamine.

— Adult with congestion triggered by cold air, perfumes, spicy food, no itch, negative allergen testing. Best therapy? → Intranasal azelastine ± ipratropium.

— Patient on INCS for 6 weeks still symptomatic. Next step? → Verify adherence and spray technique, then add intranasal antihistamine (combination spray).

— Failed INCS + antihistamine + avoidance after 3 months. Next step? → Refer for allergen testing and immunotherapy evaluation.

— Patient on daily cetirizine has negative skin prick test. Best next step? → Stop antihistamine 5–7 days and repeat, or order serum-specific IgE.

— Toddler with unilateral foul-smelling purulent discharge. → Nasal foreign body, refer ENT, not AR.

— Adult with saddle nose, septal perforation, hematuria, hemoptysis. → Order c-ANCA/PR3, urinalysis, refer rheumatology.

— Patient develops hives and hypotension after injection. → IM epinephrine 0.3 mg lateral thigh, supine with legs up, O2, IV fluids, observe ≥4 hours.

— Treat AR with INCS, audiology referral; consider tympanostomy if effusion persists ≥3 months.

Board pearl: When the stem describes a textbook AR presentation and asks for the "most effective" medication, the answer is almost always an intranasal corticosteroid — even when a non-sedating oral antihistamine is a tempting distractor.

Stem 1 — Classic uncomplicated AR:

Stem 2 — Pregnancy:

Stem 3 — Rhinitis medicamentosa:

Stem 4 — Drug-induced rhinitis:

Stem 5 — Vasomotor rhinitis:

Stem 6 — Failed first-line therapy:

Stem 7 — Immunotherapy candidate:

Stem 8 — Skin testing pitfall:

Stem 9 — Red flag presentation:

Stem 10 — GPA mimic:

Stem 11 — Anaphylaxis during SCIT:

Stem 12 — Pediatric AR + OME + speech delay:

One-Line Recap

Allergic rhinitis is an IgE-mediated, clinically diagnosed atopic disease whose stepwise outpatient management — environmental avoidance, then daily intranasal corticosteroid as the most effective monotherapy, then add-on intranasal antihistamine, and finally allergen immunotherapy for refractory disease — also improves asthma control and quality of life when applied consistently with attention to special populations, drug safety, and longitudinal follow-up.

Step 3 management: Master the algorithm — avoid → INCS → add intranasal antihistamine → immunotherapy — and you will answer the vast majority of allergic rhinitis vignettes correctly while practicing high-value, guideline-concordant ambulatory care.

Diagnose clinically with the tetrad of sneezing, clear rhinorrhea, congestion, and itching plus pale boggy turbinates; reserve allergen-specific testing for refractory cases or immunotherapy planning, and remember to hold antihistamines 5–7 days before skin prick testing.

Start with an intranasal corticosteroid daily (mometasone, fluticasone, budesonide), counsel spray technique aimed laterally, set expectations for 2-week peak effect, and reassess at 2–4 weeks; escalate to combination intranasal antihistamine before adding systemic agents.

Tailor to special populations: budesonide and loratadine/cetirizine in pregnancy; avoid first-generation antihistamines and systemic decongestants in elderly; identify drug-induced rhinitis (ACEi, tamsulosin) and discontinue rather than layering therapy; refer for immunotherapy after 3 months of failed optimized therapy.

Integrate safety and red flags: unilateral symptoms, epistaxis, anosmia, saddle nose, or systemic features demand workup beyond AR; counsel montelukast's neuropsychiatric boxed warning; document informed consent and epinephrine autoinjector training for immunotherapy; co-manage asthma because controlling allergic rhinitis improves asthma outcomes under the united-airways model.